University of California

Synamem Corporation

Proteomic Systems, Inc.

John T Groves

Morrison Ulman

Joe W Gray

Jeremy T Blitzer

Khalid Salaita

Steven G Boxer

Victoria Yamazaki

Debopriya Das

Robert J Schafer

Miki (Vikky) Yamazaki

Michael M Baksh

Luat T Nguyen

Pradeep M Nair

Michal Jaros

Vikky Yamazaki

A signature of a condition of a live cell is established in an assay that allows distribution of the receptors on the cell surface in response to binding a ligand. The receptors can be optically detected and quantified to provide a value for the condition, Test drugs can be screened for therapeutic potential in the assay: a potentially efficacious drug is identified by an ability to modulate an established signature. The receptor distribution signature can be corroborated with an mRNA expression profile of several genes, indicating, for example, metastasis.

Spatial biomarker of disease and detection of spatial organization of cellular receptors

A membrane-coated particle composition and methods comprising a particle surrounded by a native cell membrane are disclosed. The cell membrane may contain selected receptors or binding components. At least a portion of the receptors or binding components are oriented on the membrane-coated particle in the same or similar orientation as in the native cell membrane. The membrane-coated particle(s) finds use, for example, in contexts of basic research, proteomics, drug discovery, drug delivery, medical diagnostics, and aspects of patient care.

Membrane-coated particles

A method and assay are described for measuring the interaction between a ligand and an analyte. The assay can include a suspension of colloidal particles that are associated with a ligand of interest. The colloidal particles are maintained in the suspension at or near a phase transition state from a condensed phase to a dispersed phase. An analyte to be tested is then added to the suspension. If the analyte binds to the ligand, a phase change occurs to indicate that the binding was successful.

Detection of molecular interactions

Membrane-based assays using surface detector array devices suitable for use with a biosensor are disclosed. The device is formed of a substrate having a surface defining a plurality of distinct bilayer-compatible surface regions separated by one or more bilayer barrier regions. The bilayer-compatible surface regions carry on them, separated by an aqueous film, supported fluid bilayers. The bilayers may contain selected receptors or biomolecules. A bulk aqueous phase covers the bilayers on the substrate surface. Arrays may be engineered to display natural membrane materials in a native fluid bilayer configuration, permitting high-throughput discovery of drugs that target and affect membrane components. The membrane-based assays detect binding events by monitoring binding-induced changes in one or more physical properties of fluid bilayers.

Membrane-based assays

A surface detector array device suitable for use with a biosensor is disclosed. The device is formed of a substrate having a surface defining a plurality of distinct bilayer-compatible surface regions separated by one or more bilayer barrier regions. The bilayer-compatible surface regions carry on them, separated by a film of aqueous, supported fluid bilayers. The bilayers may contain selected receptors or biomolecules. A bulk aqueous phase covers the bilayers on the substrate surface. Multiplexed assays using the surface detector array device of the present invention are disclosed, as are automated methods for making the surface detector array device that enable formation of arrays wherein the composition of the individual, addressable bilayer regions is unrestricted.

Biosensor arrays and methods

Growing community of inventors

Berkeley, CA, United States of America

John T Groves